glp1ledger

Wegovy vs Ozempic: The Same Molecule Under Four Separate FDA Applications

This is not a comparison of two drugs. It is one molecule, semaglutide, marketed under two brand names and four separate approvals — and the line between the brands is not the one most people assume.

Ronald R · Edited by Caroline S · Published 2026-09-13

Illustration: Two unbranded white boxes of different sizes on a neutral kitchen counter, softly lit.
Illustration

Search interest treats this as a comparison, and it is not one. Wegovy and Ozempic contain the same molecule — semaglutide — from a single manufacturer, Novo Nordisk. There is no head-to-head trial because there is nothing to randomise between at the level of the drug.

What there is instead is a regulatory structure, and it explains more about what happens to a patient than any efficacy number could. In the United States semaglutide is sold under four separate FDA applications across two brand names, and the boundary between those brands is not the boundary most readers assume.

Labels read 13 September 2026 from DailyMed, the National Library of Medicine's index of current FDA labelling. Nothing here is medical advice, and nothing here is a dose or a schedule; our editorial standards explain why.

One molecule, four approvals

Product Application Brand Route
Ozempic injection NDA 209637 Ozempic Injection
Ozempic tablets (labelled with Rybelsus) NDA 213051 Ozempic Oral
Wegovy injection NDA 215256 Wegovy Injection
Wegovy tablets NDA 218316 Wegovy Oral

The first thing this table kills is the pen-versus-pill shorthand. Both brands now exist in both routes. Anyone who has learned that Ozempic is the injection and the oral version is something else is working from a market that no longer exists — and anyone told that "the pill" is the Wegovy product is being told half of it.

The second thing it shows is where the brand boundary actually sits: the disease. Ozempic is the type 2 diabetes brand. Wegovy is the obesity, cardiovascular and liver brand. Every other difference between them descends from that one division.

What each brand is approved to treat

Ozempic injection Ozempic tablet Wegovy injection Wegovy tablet
Glycaemic control in type 2 diabetes Yes Yes — —
Long-term weight reduction, adults — — Yes Yes
Weight reduction, patients aged 12 and older — — Yes —
Cardiovascular risk reduction Yes — with type 2 diabetes and established CV disease Yes — type 2 diabetes, at high risk Yes — established CV disease with obesity or overweight Yes — established CV disease with obesity or overweight
Chronic kidney disease outcomes Yes — — —
Noncirrhotic MASH, F2–F3 fibrosis — — Yes (accelerated approval) —

Ozempic injection label version 20, published 10 June 2026. Ozempic tablet version 14, published 19 August 2026. Wegovy version 19, published 30 June 2026.

Three readings follow, and the third is the one nobody writes down.

Each brand holds something the other cannot claim, in both directions. Ozempic alone carries the kidney indication. Wegovy alone reaches adolescents and alone carries a liver indication. Neither brand is a superset of the other, which means there is no version of "the stronger one" that survives contact with the labels.

One of Wegovy's indications is a different kind of approval. MASH is granted under accelerated approval — approval on a surrogate endpoint while confirmatory evidence is still required. The label marks it as such. It is a real approval, and listing it alongside the others without that qualifier counts correctly and describes inaccurately.

Within each brand, the tablet and the injection are not interchangeable approvals. The Wegovy tablet has no paediatric indication and no MASH indication. The Ozempic tablet has no kidney indication, and — read closely — its cardiovascular indication covers adults with type 2 diabetes "at high risk for these events" while the Ozempic injection's requires established cardiovascular disease. The same brand name, the same molecule, the same manufacturer, and a different qualifying population depending on which form is dispensed.

The one indication they share, and the condition that decides it

Strip away everything each brand holds alone and one claim is left standing on both: reduction of the risk of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke, in adults with established cardiovascular disease.

The words are nearly identical. What differs is the second condition a patient must have.

  • Under Ozempic, established cardiovascular disease plus type 2 diabetes.
  • Under Wegovy, established cardiovascular disease plus obesity or overweight.

So the same molecule, prescribed for the same cardiovascular purpose, in a patient with the same cardiovascular disease, is written under one brand or the other according to which other condition that person has. This is the clearest statement available of what these two brands really are: not two drugs, but two doors into one molecule, each with its own admission requirement.

It is also why coverage so often diverges between them for the same person. A plan is not comparing chemicals; it is reading an indication. The statutory machinery that makes weight-loss use a distinct category — and the identical structure Congress wrote deliberately for a different drug class years earlier — is on our insurance coverage page.

The combination warning that appears on one label only

There is a practical question behind a great deal of "Wegovy vs Ozempic" searching: whether someone could be on both, or could switch without a gap, or could add one to the other.

The Wegovy label answers it. Under Limitations of Use it states that concomitant use of Wegovy tablets or Wegovy injection with other semaglutide-containing products, or with any other GLP-1 receptor agonist, is not recommended.

The Ozempic labels do not. The phrase "semaglutide-containing" appears three times in the Wegovy document and zero times in either the Ozempic injection label or the Ozempic tablet label.

The underlying point is symmetrical — taking two semaglutide products together is the same event whichever one is named first — but the labelling is not, and a reader who checks only the Ozempic label will not find the sentence. This is worth knowing precisely because product labels are where people are told to look. The asymmetry is a labelling artefact, most likely of the order in which indications and applications were approved, and it is not a statement that one combination is safer than the other.

For comparison, the tirzepatide pair carries the warning on both sides: the Zepbound label states that coadministration with other tirzepatide-containing products or with any GLP-1 receptor agonist is not recommended, and so does Mounjaro's. We set that pair out on Zepbound vs Wegovy and Mounjaro vs Ozempic.

On price, the expected order is reversed

The intuition is that the diabetes brand will be the cheaper one. It is not. Ozempic costs more per milligram than Wegovy at the top of each range, and our Ozempic cost page works through the published figures and the arithmetic behind that. The Wegovy cost page carries the other brand's self-pay terms, and the cost hub holds the category table with the date each figure was read.

Prices are not re-derived on this page. Carrying them from the dated pages rather than restating them is deliberate: a price quoted twice in two places is a price that will eventually be wrong in one of them.

What this page does not answer

It does not say which brand anyone should be prescribed, and it contains no dose and no schedule. The strengths at which each brand is approved appear on the cost pages as price tiers, which is the only place a number of that kind belongs on this site.

It also does not answer how semaglutide compares with tirzepatide — that is a real comparison between different molecules, and it is on tirzepatide vs semaglutide at the molecule level and on Zepbound vs Wegovy at the brand level.

What it establishes is that "Wegovy vs Ozempic" has no pharmacological answer and a complete regulatory one. The molecule is identical. The applications, the approved uses, the qualifying conditions, the combination warning and the price per milligram are not — and every one of those differences is readable from a document anyone can open.

Sources

Labels are revised often and indications widen between versions. Every claim above is tied to a named label version and the date it was read.

Frequently asked questions

What is the difference between Wegovy and Ozempic?

They contain the same molecule, semaglutide, from the same manufacturer. What differs is what each is approved to treat. Ozempic is approved for type 2 diabetes — glycaemic control, cardiovascular risk reduction in adults with established cardiovascular disease, and a kidney indication in chronic kidney disease. Wegovy is approved for weight management, for cardiovascular risk reduction in adults with established cardiovascular disease and obesity or overweight, and for noncirrhotic MASH with moderate to advanced fibrosis. The prescription is written under an indication, so the brand follows the diagnosis rather than the other way round.

Is Wegovy just a higher dose of Ozempic?

That is the common shorthand and it is not what separates the two brands. They are distinct FDA applications with distinct labels, distinct approved indications, distinct clinical trial programmes and distinct dose forms — and each brand now sells both an injection and a tablet. The dose ranges do differ, but a difference in strength is not the reason there are two brands. Two products would not need separate applications and separate trials to differ only by strength.

Can someone take Wegovy and Ozempic together?

One of the two labels answers this directly and the other does not mention it. Wegovy's Limitations of Use state that concomitant use with other semaglutide-containing products, or with any other GLP-1 receptor agonist, is not recommended. The Ozempic injection and tablet labels contain no equivalent sentence — the phrase does not appear in either document. The pharmacological point is symmetrical whichever product is being asked about; the labelling is not. What follows for any individual is a question for a prescriber.

Which is cheaper, Wegovy or Ozempic?

Ozempic costs more per milligram than Wegovy at the top of each range, which is the opposite of what most people expect from a diabetes drug and a weight-loss drug of the same molecule. Our [Ozempic cost page](/cost/ozempic) works through the figures and the reason, and our [Wegovy cost page](/cost/wegovy) carries that brand's published self-pay terms. Both were read from the manufacturer's own material in September 2026 and both are dated, because an undated price in this category looks current when it is not.

Does insurance treat them differently?

It usually does, and the reason is the indication rather than the molecule. A plan that excludes drugs used for weight loss and covers drugs used for diabetes is distinguishing between uses, not between chemicals — which is exactly why the same semaglutide can be covered under one brand and refused under another for the same person. The statutory mechanism behind that, including the precedent Congress wrote for a different drug class, is set out on our [insurance coverage page](/glp-1-insurance-coverage).

Is Ozempic approved for weight loss?

No. Ozempic's approved indications are glycaemic control in adults with type 2 diabetes, cardiovascular risk reduction in adults with established cardiovascular disease, and reduction of kidney outcomes in adults with chronic kidney disease. Weight reduction is an approved use of the same molecule under the Wegovy brand. Weight change is reported in Ozempic's trials as an effect that occurs, not as an indication.

Which brand is approved for teenagers?

The Wegovy injection is indicated for weight reduction in paediatric patients aged 12 years and older with obesity. Neither Ozempic form carries a paediatric indication, and neither does the Wegovy tablet — so within the brand that has the adolescent approval, only one of the two dose forms holds it.

Why are there four FDA applications for one molecule?

Each combination of dose form and approved use went through its own application: Ozempic injection under NDA 209637, the Ozempic tablet sharing a label with Rybelsus under NDA 213051, the Wegovy injection under NDA 215256 and the Wegovy tablet under NDA 218316. A new indication or a new route of administration requires its own evidence, so the regulatory structure follows the trials rather than the chemistry. It is why the same molecule can carry a kidney indication in one document and a liver indication in another.